Storia in 5 fonti

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

Raccontata dastatnews.commorningstar.combiopharmadive.combenzinga.comendpoints.news

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo21 h fa

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

originale

statnews.com1 g fa

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

Leggi questa versione → originale

endpoints.news10 h fa

Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout

Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test by year’s end.

Leggi questa versione → originale

benzinga.com15 h fa

Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L

Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.

Leggi questa versione → originale

morningstar.com1 g fa

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%,…

A single dose of Lilly's VERVE-102 base editor reduced PCSK9 by up to 88% and LDL-C by up to 62% in Phase 1b, with effects sustained for 18 months across 35 patients with familial hypercholesterolemia or premature CAD. For health tech and biopharma investors, this signals a credible shift from chronic lipid-lowering therapy (statins, PCSK9 inhibitors) to a one-time genomic intervention, with Phase 2 enrollment starting before end of 2026.

Leggi questa versione → originale

Timeline cronologica

1. lunedì 25 maggio 2026·statnews.com
   

   Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

   Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

2. lunedì 25 maggio 2026·morningstar.com
   

   A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting…

   A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for…

3. martedì 26 maggio 2026·biopharmadive.com
   

   Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

   The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

4. martedì 26 maggio 2026·benzinga.com
   

   Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L

   Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.

5. martedì 26 maggio 2026·endpoints.news
   

   Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout

   Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test…

6. martedì 26 maggio 2026·statnews.com
   

   Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more

   Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial